Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5325045 | 0.88 | CTSK (0.59) | CTSKMAOBCTSSCTSLCTSB | |
| SCHEMBL5898129 | 0.88 | CTSK (0.59) | CTSKMAOBCTSSCTSLCTSB | |
| SCHEMBL5325046 | 0.88 | CTSK (0.59) | CTSKMAOBCTSSCTSLCTSB | |
| SCHEMBL3740424 | 0.81 | NR4A1 (0.51) | CTSKCTSSCTSLCTSBNR4A1 | |
| SCHEMBL3731879 | 0.81 | CTSL (0.53) | CTSKCTSSCTSLCTSBNR4A1 | |
| SCHEMBL8671882 | 0.80 | CTSL (0.63) | CTSKCTSSCTSLCTSBELANE | |
| SCHEMBL220569 | 0.80 | CTSL (0.63) | CTSKCTSSCTSLCTSBELANE | |
| SCHEMBL2978398 | 0.80 | CTSL (0.63) | CTSKCTSSCTSLCTSBELANE | |
| SCHEMBL1287168 | 0.80 | CTSL (0.63) | CTSKCTSSCTSLCTSBELANE | |
| SCHEMBL8492505 | 0.80 | MME (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026515-B2 | Optically active amine derivatives and preparation process therefor | MITSUI CHEMICALS, INC. (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20040030144-A1 | Optically active amine derivative and method of synthesis | MITSUI CHEMICALS, INC. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1340743-A1 | OPTICALLY ACTIVE AMINE DERIVATIVE AND METHOD OF SYNTHESIS | Mitsui Chemicals, Inc. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030144-A1 | Optically active amine derivative and method of synthesis | ALDH7A1, AADAT, KMO | CTSK 1631/4885MAOB 196/4885CTSS 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.